Cochrane 2026 Update Reinforces E-Cigarettes as More Effective Than NRT for Smoking Cessation

Executive summary

Cochrane’s 2026 update of its living systematic review on electronic cigarettes for smoking cessation includes 80 randomized controlled trials with 29,861 adult participants. The analysis adds nine new trials and reaffirms a high-certainty finding: nicotine e-cigarettes significantly improve long-term smoking cessation rates compared to nicotine replacement therapy (NRT). Absolute quit rates are approximately 10% for e-cigarette users versus 6% for NRT users. No clear difference in serious adverse events was observed. The review underscores the importance of evidence-based policy, particularly as regulators debate product access and harm reduction strategies.

Regulatory signal: High-certainty evidence of superior efficacy strengthens the case for regulatory support of nicotine e-cigarettes as cessation tools.

What happened

The Cochrane review, now a living document, was updated in September 2026 with the inclusion of nine new randomized controlled trials. The total dataset now comprises 80 trials and 29,861 adult smokers attempting to quit. The primary outcome measured was abstinence from smoking for at least six months, verified by biochemical testing in most studies. The review compared nicotine e-cigarettes (including both first- and second-generation devices) with nicotine replacement therapy (NRT), such as patches, gum, and lozenges.

Results show a consistent and statistically significant advantage for e-cigarettes: an absolute increase in cessation rates of about 4 percentage points (10% vs. 6%). This effect remains robust across subgroups, including different age groups, smoking intensity, and baseline nicotine dependence levels. The review found no clear evidence of increased serious adverse events in the e-cigarette group, though long-term safety data—particularly for newer pod systems and high-nicotine formulations—remains limited.

Why it matters

This update is a pivotal moment in the scientific consensus around vaping as a cessation tool. Cochrane’s high-certainty rating—based on consistent results, low risk of bias, and large sample sizes—lends substantial weight to the argument that e-cigarettes are not merely alternatives to smoking but effective public health interventions. The findings directly challenge long-standing regulatory skepticism in some jurisdictions that have treated e-cigarettes as a gateway or risk factor without sufficient evidence of benefit.

For public health agencies, the data supports a shift from risk-averse to harm-reduction-oriented policy. The review also highlights the limitations of NRT, which has long been the gold standard despite lower efficacy. The 4% absolute improvement may seem modest, but in population-level terms, it translates to tens of thousands of additional quitters annually in high-smoking countries.

Market impact

Regulatory clarity based on this evidence could accelerate market access for newer e-cigarette technologies, particularly pod systems and higher-nicotine formulations that align with user preferences and cessation outcomes. Manufacturers of nicotine e-cigarettes may gain stronger footing in markets where product availability is restricted or taxed disproportionately.

Pharmaceutical companies producing NRT products may face increased competitive pressure. While NRT remains a viable option for some users, the evidence suggests it is less effective than e-cigarettes for the majority. This could influence insurance coverage decisions, pharmacy formularies, and public health prescribing guidelines.

Consumer trust in e-cigarettes as cessation tools may rise, particularly among current smokers seeking alternatives. However, the market remains sensitive to regulatory shifts, and public messaging must balance efficacy with safety concerns, especially around youth use and long-term exposure.

Regulatory impact

The Cochrane update strengthens the scientific foundation for regulatory bodies to reevaluate their stance on e-cigarettes. In jurisdictions where e-cigarettes are treated as tobacco products or subject to stringent restrictions (e.g., flavor bans, device limits, or marketing restrictions), this evidence could prompt reconsideration.

Regulators in the UK, Canada, and Australia—where e-cigarettes are already integrated into cessation services—may use this update to expand access and funding. Conversely, countries with stricter policies (e.g., certain EU member states, the U.S. FDA’s ongoing evaluation of modified risk tobacco product (MRTP) applications) may face pressure to align their frameworks with the latest evidence.

Notably, the review does not assess the impact of non-nicotine e-cigarettes or synthetic nicotine products, leaving regulatory questions about those categories unresolved. However, the findings apply directly to nicotine-containing devices, which dominate the current market.

Who is affected

• Regulators: Public health agencies and tobacco control authorities in high-income countries with active e-cigarette policies.
• Healthcare providers: Clinicians, stop-smoking advisors, and pharmacists advising patients on cessation methods.
• Pharmaceutical companies: Manufacturers of NRT products facing potential market erosion.
• Device and e-liquid manufacturers: Producers of nicotine e-cigarettes, especially those with higher nicotine delivery systems or refillable pod designs.
• Public health funders: Government and nonprofit organizations funding smoking cessation programs.
• Smokers: Adult users seeking effective, accessible, and evidence-backed cessation tools.

Dawsen Take

Market signal: The high-certainty evidence of e-cigarette superiority over NRT may drive policy changes that expand access and reduce barriers to use in cessation programs.

This update is not a call to promote vaping but a clear signal that nicotine e-cigarettes are a proven tool for reducing smoking-related harm. Regulators and public health officials must now decide whether to act on the evidence—or continue to prioritize precaution over proven efficacy. The gap between science and policy remains a central challenge in tobacco harm reduction.

What to watch

Monitor regulatory responses in key markets, particularly the UK’s NHS guidance, Canada’s Health Canada product evaluations, and the U.S. FDA’s upcoming decisions on MRTP applications. Look for shifts in cessation program funding and inclusion of e-cigarettes in national tobacco control strategies. Also track how this evidence influences public messaging, especially around youth use, to ensure that benefits for adult smokers are not overshadowed by unintended consequences.

Longer-term, the review underscores the need for ongoing safety monitoring of newer device types and formulations. While the current evidence supports short- and medium-term safety, real-world data on chronic exposure remains limited.

For more daily vaping news, check out dawsenai.com.

Original source: 2FIRSTS | Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT